Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2021-11-05 00:00:00 ET · period of report 2021-11-04 · accession 0001209191-21-063210 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-05 | 2021-11-04 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +10.6K | 96.3K | +12% | +$3,180 |
| D | 2021-11-05 | 2021-11-04 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $50.00 | -10.6K | 85.7K | -11% | -$530.0K |
| D | 2021-11-05 | 2021-11-04 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.00 | -10.6K | 119.1K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-04 | M | A | 10,600 | $0.3 | 96,300 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-04 | S | D | 10,600 | $50.00 | 85,700 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2021-11-04 | M | D | 10,600 | $0.00 | 119,105 | D | $0.3 · — to 2028-03-25 | 10,600 Common Stock | (F2) Immediately exercisable. |